M. H. Andersen

发表

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

I. Svane, P. Straten, M. Brimnes, 2011, Scandinavian journal of immunology.

The targeting of immunosuppressive mechanisms in hematological malignancies

M. Andersen, M. H. Andersen, 2014, Leukemia.

The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients

J. Becker, P. Straten, M. Andersen, 2005, Leukemia.

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)

J. Olsen, J. Berthelsen, C. Geisler, 2014, Leukemia.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.

Functional characterization of Foxp3-specific spontaneous immune responses

I. Svane, A. Woetmann, N. Odum, 2013, Leukemia.

Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

M. Donia, I. Svane, P. Straten, 2012, Scandinavian journal of immunology.

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

I. Svane, S. K. Larsen, M. Andersen, 2014, Leukemia.